Switch theme
Sign up to access all valuation multiples
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.
1988
10
LTM Revenue $0.4M
LTM EBITDA -$10.1M
$15.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medivir has a last 12-month revenue (LTM) of $0.4M and a last 12-month EBITDA of -$10.1M.
In the most recent fiscal year, Medivir achieved revenue of $0.4M and an EBITDA of -$12.4M.
Medivir expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medivir valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.4M | XXX | $0.4M | XXX | XXX | XXX |
| Gross Profit | $0.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$10.1M | XXX | -$12.4M | XXX | XXX | XXX |
| EBITDA Margin | -2356% | XXX | -3439% | XXX | XXX | XXX |
| EBIT | -$10.2M | XXX | -$13.2M | XXX | XXX | XXX |
| EBIT Margin | -2392% | XXX | -3676% | XXX | XXX | XXX |
| Net Profit | -$10.0M | XXX | -$12.7M | XXX | XXX | XXX |
| Net Margin | -2331% | XXX | -3540% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medivir's stock price is SEK 2 (or $0).
Medivir has current market cap of SEK 201M (or $20.8M), and EV of SEK 150M (or $15.5M).
See Medivir trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.5M | $20.8M | XXX | XXX | XXX | XXX | $-0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medivir has market cap of $20.8M and EV of $15.5M.
Medivir's trades at 43.1x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Medivir's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medivir has a P/E ratio of -2.1x.
See valuation multiples for Medivir and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20.8M | XXX | $20.8M | XXX | XXX | XXX |
| EV (current) | $15.5M | XXX | $15.5M | XXX | XXX | XXX |
| EV/Revenue | 36.1x | XXX | 43.1x | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -1.5x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | 36.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | -1.2x | XXX | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedivir's last 12 month revenue growth is -3%
Medivir's revenue per employee in the last FY averaged $36K, while opex per employee averaged $1.4M for the same period.
Medivir's rule of 40 is -1125% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medivir's rule of X is -2364% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medivir and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -3% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | -2356% | XXX | -3439% | XXX | XXX | XXX |
| EBITDA Growth | -20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1125% | XXX | -3442% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2364% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $36K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3776% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medivir acquired XXX companies to date.
Last acquisition by Medivir was XXXXXXXX, XXXXX XXXXX XXXXXX . Medivir acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medivir founded? | Medivir was founded in 1988. |
| Where is Medivir headquartered? | Medivir is headquartered in Sweden. |
| How many employees does Medivir have? | As of today, Medivir has 10 employees. |
| Who is the CEO of Medivir? | Medivir's CEO is Mr. Jens Lindberg. |
| Is Medivir publicy listed? | Yes, Medivir is a public company listed on STO. |
| What is the stock symbol of Medivir? | Medivir trades under MVIR ticker. |
| When did Medivir go public? | Medivir went public in 1996. |
| Who are competitors of Medivir? | Similar companies to Medivir include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Medivir? | Medivir's current market cap is $20.8M |
| What is the current revenue of Medivir? | Medivir's last 12 months revenue is $0.4M. |
| What is the current revenue growth of Medivir? | Medivir revenue growth (NTM/LTM) is -3%. |
| What is the current EV/Revenue multiple of Medivir? | Current revenue multiple of Medivir is 36.1x. |
| Is Medivir profitable? | Yes, Medivir is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medivir? | Medivir's last 12 months EBITDA is -$10.1M. |
| What is Medivir's EBITDA margin? | Medivir's last 12 months EBITDA margin is -2356%. |
| What is the current EV/EBITDA multiple of Medivir? | Current EBITDA multiple of Medivir is -1.5x. |
| What is the current FCF of Medivir? | Medivir's last 12 months FCF is -$12.7M. |
| What is Medivir's FCF margin? | Medivir's last 12 months FCF margin is -2961%. |
| What is the current EV/FCF multiple of Medivir? | Current FCF multiple of Medivir is -1.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
